The reversed pattern of gene expression compared to that induced by treatment with low-dose IL-2 immunotherapy in T1D [4] suggests that interval dosing of low-dose IL-2 for a month promotes a prolonged regulatory environment, which could potentially hasten the restoration of normal immune homeostasis in recovered COVID-19 patients. The gene discussed is IL2; the disease is type 1 diabetes mellitus.